The study is testing the safety of a drug called LY4006895 on people with early Alzheimer's Disease (AD) and healthy volunteers. Alzheimer's Disease is a condition that affects memory and thinking. The study has two parts. Part A will last about 29 weeks and involves giving one dose of the drug to healthy people. Part B will last about 61 weeks and involves giving multiple doses to those with early AD symptoms. The study checks how the drug moves in the blood and how long it stays in the body.
- Healthy people and those with early AD can join, but they must not have other serious illnesses.
- Participants for Part B must have up to 2 study partners who can help with the study visits and stay in contact.
- Women who are pregnant or breastfeeding cannot join, and participants must not have used certain drugs recently.
Participants will need to do blood tests and attend visits. It is important for each person to feel comfortable with the time and commitment needed for the study.
How understandable was the trial content above?
Hard to understand
Easy to understand